GlaxoSmithKline Pharmaceuticals Limited — Board Meeting, 01-08-2025: Outcome of Board Meeting

GlaxoSmithKline Pharma's board has approved its consolidated financial results for the quarter ended June 30, 2025. Revenue from operations stood at ₹805.17 Cr, a slight dip from ₹814.65 Cr in the same quarter last year. However, the company reported a strong net profit after tax of ₹205.01 Cr, a significant increase from ₹182.33 Cr year-on-year. This performance translates to an EPS of ₹12.10, up from ₹10.76. Investors should note the impressive profit growth despite a marginal revenue change.